Cdc37通过自噬参与多发性骨髓瘤对硼替佐米耐药
本研究在硼替佐米耐药的骨髓瘤细胞株ANBL-6.BR中发现Cdc37低表达而LC3b高表达,上调Cdc37可抑制LC3b并增加硼替佐米敏感性;在NCI-H929中抑制Cdc37导致硼替佐米耐药和自噬激活,氯喹可逆转该耐药。结论提示Cdc37可能通过调控自噬参与硼替佐米耐药。
要点
- 耐药株ANBL-6.BR中Cdc37低表达、LC3b高表达。
- 上调Cdc37可抑制LC3b并增加骨髓瘤细胞对硼替佐米的敏感性。
- 抑制Cdc37致硼替佐米耐药和自噬升高,氯喹可逆转该耐药。
核心结论
- Cdc37可能通过调控细胞自噬参与多发性骨髓瘤细胞对硼替佐米的耐药过程。
研究设计与样本
- 体外细胞研究,使用硼替佐米耐药细胞株ANBL-6.BR和骨髓瘤细胞株NCI-H929。
- 采用qRT-PCR和Western blot检测Cdc37及LC3b表达,慢病毒转染上调Cdc37,shRNA干扰下调Cdc37。
- 用流式细胞术检测硼替佐米诱导的凋亡,CCK-8法评估硼替佐米敏感性,Western blot检测AKT/mTOR通路及自噬相关蛋白。
- 用自噬抑制剂氯喹处理NCI-H929细胞,流式细胞术分析其对硼替佐米敏感性的影响。
主要发现
- Cdc37在硼替佐米耐药细胞株ANBL-6.BR中低表达,而自噬相关基因LC3b在耐药株中高表达。
- 上调ANBL-6.BR细胞中Cdc37表达可抑制LC3b表达,并增加多发性骨髓瘤细胞对硼替佐米的敏感性。
- 在NCI-H929细胞中抑制Cdc37表达导致硼替佐米耐药,同时引起自噬水平升高。
- 自噬抑制剂氯喹可逆转Cdc37下调所引起的硼替佐米耐药。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the role of cell division cycle protein 37 (Cdc37) mediating bortezomib (BTZ) resistance in multiple myeloma (MM) via the regulation of autophagy activity to provide a novel strategy for MM therapy. Methods: The expressions of Cdc37 and LC3b were investigated in BTZ-resistant MM cell line ANBL-6.BR using quantitative real-time PCR (qRT-PCR) and western blot (WB) analysis. Cdc37 was upregulated in ANBL-6.BR cells owing to lentivirus transfection. The LC3b expression was detected with WB, and BTZ-induced apoptosis was explored using flow cytometry. Cdc37 was then down-regulated by shRNA in the MM cell line NCI-H929. Sensitivity of BTZ was evaluated using CCK-8 analysis. WB analysis was performed to check the expression of the AKT/mTOR pathway and autophagy-associated proteins. The sensitivity of NCI-H929 cells to BTZ in the presence of autophagy inhibitor chloroquine (CQ) was analyzed using flow cytometry. Results: Cdc37 was down-regulated, while autophagy-associated gene LC3b was upregulated in BTZ-resistant cell line ANBL-6.BR. Up-regulated Cdc37 in ANBL-6.BR cells could inhibit LC3b expression and increase the sensitivity of MM to BTZ. Suppressing Cdc37 expression in MM cell line NCI-H929 induced BTZ resistance and autophagy activation, while CQ could rescue BTZ resistance caused by Cdc37 inhibition. Conclusion: Cdc37 may participate in BTZ resistance in MM via the regulation of autophagy activity. 目的: 探索细胞分裂周期蛋白37(Cdc37)通过调控细胞自噬参与多发性骨髓瘤(MM)对硼替佐米(BTZ)耐药的机制,为MM的治疗提供新的思路。 方法: 应用实时荧光定量PCR(qRT-PCR)和Western blot(WB)技术测定BTZ耐药细胞株ANBL-6.BR中Cdc37及自噬相关基因LC3b的表达水平。采用慢病毒转染技术上调ANBL-6.BR细胞中Cdc37的表达水平,WB技术检测LC3b的表达,流式细胞术检测BTZ诱导的细胞凋亡。采用shRNA干扰技术下调MM细胞株NCI-H929中Cdc37的表达水平,CCK-8法进一步验证Cdc37低表达与BTZ耐药相关,WB技术检测AKT/mTOR信号通路及自噬相关蛋白的表达变化;通过流式细胞术检测自噬抑制剂氯喹(CQ)是否可以增加耐药MM细胞对BTZ的敏感性。 结果: Cdc37在BTZ耐药细胞株ANBL-6.BR中低表达,而自噬相关基因LC3b在耐药株中高表达。上调ANBL-6.BR细胞中Cdc37的表达水平可抑制LC3b的表达,且增加了MM细胞对BTZ的敏感性。在MM细胞系NCI-H929中抑制Cdc37的表达导致BTZ耐药,同时引起自噬水平升高。而自噬抑制剂CQ可逆转Cdc37下调所引起的BTZ耐药。 结论: Cdc37可能通过调控细胞自噬参与MM细胞对BTZ的耐药过程。.
引用
- Liu LT, Deng SH, Zang MR, et al. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32810966. doi:10.3760/cma.j.issn.0253-2727.2020.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。